3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Sell
30
BIO Quote, Financials, Valuation and Earnings
Last price:
$254.68
Seasonality move
:
9.34%
Day range:
$244.00 - $250.94
52-week range:
$244.00 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.04x
Volume:
198.3K
Avg. volume:
322.4K
1-year change:
-27.17%
Market cap:
$6.9B
Revenue:
$2.6B
EPS (TTM):
-$65.04
Analysts' Opinion
-
Consensus RatingBio-Rad Laboratories has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $372.83, Bio-Rad Laboratories has an estimated upside of 52.17% from its current price of $245.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $315.00 representing 100% downside risk from its current price of $245.01.
Fair Value
-
According to the consensus of 4 analysts, Bio-Rad Laboratories has 52.17% upside to fair value with a price target of $372.83 per share.
BIO vs. S&P 500
-
Over the past 5 trading days, Bio-Rad Laboratories has underperformed the S&P 500 by -0.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Rad Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Rad Laboratories revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Rad Laboratories reported revenues of $667.5M.
Earnings Growth
-
Bio-Rad Laboratories has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bio-Rad Laboratories reported earnings per share of -$25.57.
Enterprise value:
6.4B
EV / Invested capital:
0.82x
Price / LTM sales:
2.69x
EV / EBIT:
--
EV / Revenue:
2.49x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
24.04x
Price / Operating cash flow:
25.98x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4B
Return On Assets:
-16.9%
Net Income Margin (TTM):
-71.86%
Return On Equity:
-23.87%
Return On Invested Capital:
-20.67%
Operating Margin:
8.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.7B | $2.6B | $681.1M | $667.5M | |
| Gross Profit | $1.6B | $1.4B | $1.4B | $366.3M | $341.9M | |
| Operating Income | $475.1M | $337.8M | $269M | $95.3M | $58.3M | |
| EBITDA | -$4.5B | -$654.8M | -$2.1B | $477.9M | -$857.5M | |
| Diluted EPS | -$121.25 | -$21.49 | -$65.04 | $12.14 | -$25.57 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $2B | $3.2B | $3B | $3B | |
| Total Assets | $13B | $17.8B | $13.5B | $12.3B | $9.4B | |
| Current Liabilities | $631.5M | $680.9M | $568.7M | $522.8M | $467.8M | |
| Total Liabilities | $3.1B | $4.1B | $3.9B | $3.6B | $2.8B | |
| Total Equity | $9.9B | $13.7B | $9.6B | $8.7B | $6.6B | |
| Total Debt | $2.6M | $11M | $1.2B | $1.2B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $194.4M | $374.9M | $455.2M | $81M | $124.2M | |
| Cash From Investing | -$1.2B | $20.2M | -$160.2M | $72.2M | -$30.5M | |
| Cash From Financing | $973.6M | -$425.6M | -$218.8M | -$200.6M | -$26.2M | |
| Free Cash Flow | $80.1M | $218.2M | $266.2M | $38.7M | $81.2M | |
BIO
Sector
Market Cap
$6.9B
$38.4M
Price % of 52-Week High
63.15%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
2.19%
-0.78%
1-Year Price Total Return
-27.17%
-39.05%
Beta (5-Year)
0.984
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$254.20
200-day SMA
Sell
Level
$319.54
Bollinger Bands (100)
Sell
Level
296.49 - 360.13
Chaikin Money Flow
Buy
Level
23.5M
20-day SMA
Sell
Level
$273.06
Relative Strength Index (RSI14)
Sell
Level
25.82
ADX Line
Sell
Level
46.45
Williams %R
Buy
Level
-97.4566
50-day SMA
Sell
Level
$316.39
MACD (12, 26)
Sell
Level
-20.76
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
21.1M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8785)
Sell
CA Score
(Annual)
Level (-0.378)
Buy
Beneish M-Score
(Annual)
Level (-3.6873)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.3426)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Stock Forecast FAQ
In the current month, BIO has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $372.83.
-
Where Will Bio-Rad Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Rad Laboratories share price will rise to $372.83 per share over the next 12 months.
-
What Do Analysts Say About Bio-Rad Laboratories?
Analysts are divided on their view about Bio-Rad Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories is a Sell and believe this share price will drop from its current level to $315.00.
-
What Is Bio-Rad Laboratories's Price Target?
The price target for Bio-Rad Laboratories over the next 1-year time period is forecast to be $372.83 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of BIO?
You can purchase shares of Bio-Rad Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories shares.
-
What Is The Bio-Rad Laboratories Share Price Today?
Bio-Rad Laboratories was last trading at $254.68 per share. This represents the most recent stock quote for Bio-Rad Laboratories. Yesterday, Bio-Rad Laboratories closed at $245.01 per share.
-
How To Buy Bio-Rad Laboratories Stock Online?
In order to purchase Bio-Rad Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Tesla Stock: The Bear Case
The recent stock market drop has been a punishing time…
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Alerts
Sell
5
CABO alert for Mar 14
Cable One [CABO] is down 3.97% over the past day.
Sell
38
ADBE alert for Mar 14
Adobe [ADBE] is up 4.43% over the past day.
Sell
29
CAR alert for Mar 14
Avis Budget Group [CAR] is up 11.68% over the past day.
